R. Sellar

发表

Comparative analysis of melphalan versus busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia

G. Mufti, S. Mackinnon, K. Peggs, 2019, British journal of haematology.

MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers

A. Bird, D. Harrison, A. Peter, 2003, Oncogene.

Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003

R. Hough, A. Vora, A. Moorman, 2018, British journal of haematology.

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

S. Mccarroll, D. Neuberg, B. Ebert, 2018, Science Translational Medicine.

Jak-ing Up the Plaque's Lipid Core…and Even More.

P. Libby, B. Ebert, R. Molinaro, 2018, Circulation research.

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells

B. Ebert, M. Słabicki, Steve Carr, 2022, The Journal of clinical investigation.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.

C. Craddock, S. Nagra, L. Jardine, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts

C. Craddock, S. Nagra, L. Jardine, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Impact of Alemtuzumab Scheduling on Graft Versus Host Disease Following Unrelated Donor Fludarabine and Melphalan Allografts

C. Craddock, S. Nagra, L. Jardine, 2017 .

Redefining Transplant in Acute Leukemia

H. Lazarus, A. Goldstone, R. Sellar, 2011, Current treatment options in oncology.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation

S. Beck, M. Widschwendter, V. Rakyan, 2015, Genome Medicine.

Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome

K. Stoeber, A. Khwaja, D. Linch, 2018, British journal of haematology.

Transplants for the old but not for the young?--The enigma of adult ALL.

A. Goldstone, R. Sellar, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update

K. Peggs, R. Sellar, 2014, Expert opinion on biological therapy.

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

T. Golub, S. Fröhling, B. Ebert, 2020, Nature.

Management of multidrug‐resistant viruses in the immunocompromised host

K. Peggs, R. Sellar, 2012, British journal of haematology.

Therapeutic strategies for the prevention and treatment of cytomegalovirus infection

K. Peggs, R. Sellar, 2012, Expert opinion on biological therapy.

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.

S. Carr, A. Letai, B. Ebert, 2018, Blood.

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

T. Golub, S. Fröhling, B. Ebert, 2020, Nature.

Clonal hematopoiesis and risk of chronic liver disease

Po-Ru Loh, Daniel Levy, B. Ebert, 2022, medRxiv.

Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs.

S. Carr, A. Letai, B. Ebert, 2019, Blood.

Predicting progression to AML

B. Ebert, S. Jaiswal, R. Sellar, 2018, Nature Medicine.

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

R. Hills, D. Linch, A. Burnett, 2013, Leukemia.

Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.

J. Losman, R. Sellar, 2017, Hematology/oncology clinics of North America.

Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.

K. Peggs, R. Sellar, 2012, Future oncology.

Investigation of cell cycle status in patients with acute myeloid leukaemia

R. Sellar, 2018 .

CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status.

S. Quezada, S. Mackinnon, K. Peggs, 2015, Blood.

The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation.

K. Peggs, R. Sellar, 2012, Cytotherapy.

Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT

R. Sellar, K. Thomson, K. Peggs, 2012, Bone Marrow Transplantation.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation

S. Beck, M. Widschwendter, V. Rakyan, 2015, Genome Medicine.

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

A. Khwaja, B. Davies, D. Linch, 2014, British journal of haematology.

Treatment for lymph node tuberculosis

K. Ardeshna, D. Linch, E. Corbett, 2010, British medical journal.

Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission

R. Hills, D. Linch, A. Moorman, 2011 .

Clonal haematopoiesis and risk of chronic liver disease

Andrew D. Johnson, Benjamin D. Heavner, May E. Montasser, 2023, Nature.

Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies.

S. Carr, B. Ebert, J. Cayuela, 2021, Cancer discovery.

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

S. Carr, B. Ebert, J. Cayuela, 2021, Blood cancer discovery.

BRAFV600E mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients

S. Pileri, H. Stein, A. Akarca, 2015, British journal of haematology.

Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment

K. Stoeber, A. Akarca, T. Marafioti, 2016, British journal of haematology.

Predicting progression to AML

B. Ebert, S. Jaiswal, R. Sellar, 2018, Nature Medicine.

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

A. Khwaja, B. Davies, D. Linch, 2014, British journal of haematology.

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.

John G Doench, S. Carr, A. Letai, 2018, Blood.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy.

N. Potter, C. Crawley, N. Russell, 2023, Blood.